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Pioglitazone in chronic hepatitis C not responding
to pegylated interferon-a and ribavirinq
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3Division of Therapeutic Education for Diabetes, Obesity and Chronic Diseases, University Hospital,
24 rue Micheli-du-Crest, 1211 Geneva 4, Switzerland
4Department of Medicine, City Hospital, 2300 La-Chaux-de-Fonds, SwitzerlandBackground/Aims: Insulin resistance reduces the response to interferon alfa-based therapy of chronic hepatitis C
patients. It has been speculated that improvement of insulin sensitivity might increase the chances of responding to treat-
ment of such individuals.
Methods:We started a multicenter clinical trial of retreatment of chronic hepatitis C patients, who had failed to respond
to the pegylated interferon alfa/ribavirin combination, with a triple therapy consisting in these same antivirals plus an insu-
lin-sensitizer (pioglitazone) (The INSPIRED-HCV study).
Results:None of the ﬁrst ﬁve patients fulﬁlling the inclusion criteria and included in the trial had a satisfactory virolog-
ical response after 12 weeks of retreatment, despite the fact that in at least three of them the insulin resistance score
improved. As a result, the study was terminated.
Conclusions:Diﬀerent schedules are warranted to improve insulin sensitivity prior to attempting retreatment of chronic
hepatitis C patients with insulin resistance.
 2008 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.
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Insulin resistance and diabetes are major disease
modiﬁers in chronic hepatitis C, as they increase liver
ﬁbrogenesis [1–4] and reduce the rate of response to
antivirals [5–7]. Regarding the latter, a sustained viro-
logical response (SVR) was reported to occur in 23 of
70 (32.8%) of patients with genotype 1 and insulin resis-0168-8278/$34.00  2008 European Association for the Study of the Liver.
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resistance, HOMA-IR > 2) vs. 26 of 43 (60.5%) of geno-
type 1 patients without insulin resistance (p = .007; OR,
3.12, 95% CI, 1.42–6.89) [5]. These ﬁndings were inde-
pendently conﬁrmed [6] and recently extended to non-
responders with genotypes 2 and 3 [7]. Thus, based on
our recent results [7], we [7,8] and others [5] have sug-
gested that insulin resistance should be corrected in
patients with chronic hepatitis C not responding to cur-
rently available antiviral treatment, in order to improve
response to retreatment. The modalities of this interven-
tion, however, have not been established. In addition,
the optimal HOMA-IR score to be attained has not
been identiﬁed.
We planned a prospective, multicenter study to inves-
tigate the eﬃcacy and safety of the insulin-sensitizerPublished by Elsevier B.V. All rights reserved.
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Switzerland) 15 mg QD, added to the pegylated inter-
feron-a2a (PEG-IFN-a2a) (Pegasys
TM, Roche Pharma
Schweiz AG, Reinach, Switzerland) 180 lg QW/ribavi-
rin (CopegusTM, Roche) 1000–1200 mg QD combina-
tion therapy in chronic hepatitis C patients who had
previously failed to respond (i.e. had detectable serum
HCV RNA after 12 weeks of therapy) to a pegylated
interferon-a/ribavirin combination without the insulin-
sensitizer (‘‘A pilot study of treatment with pegylated
interferon-alpha2a, ribavirin and insulin-sensitizer piog-
litazone of insulin resistance (with the exception of
diabetes) in hepatitis C virus infection”, The INSPIRED-
HCV study, registered as NCT00433069 at Clinicaltri-
als.gov). All patients had a baseline HOMA-IR score
>2 as additional inclusion criterion, because this was
the threshold discriminating responders from non-
responders in previous works [5,7]. Diabetic patients
were excluded. The trial was approved by the Ethical
Committee of the University Hospitals of Geneva, and
all patients consented to participate.2. Multiple case reports
Patient #1 was a 46-year-old female who had failed
previous treatment of PegasysTM and CopegusTM four
years earlier. A liver biopsy performed in 2004 showed
a Metavir score of A2 F3, with mild steatosis aﬀecting
20% of hepatocytes. She had a normal body weight with
a BMI of 20.8, and was not known for a hypertension or
a dyslipidemia. As concomitant medications, she was
receiving duloxetine 60 mg QD and zopiclone 7.5 mg
QD. After 12 weeks of treatment, serum HCV RNA
level did not change (from 176,000 IU/ml to
154,000 IU/ml, measured by Cobas TaqMan HCV,
Roche Diagnostics, Rotkreuz, Switzerland) and, oddly
enough, the HOMA-IR score increased from 2.65 to
11. Thus, therapy was discontinued. Her body weight
remained stable during therapy.
Patient #2 was a 49-year-old male with a liver biopsy
performed in 2003 that showed a mild chronic hepatitis,
focal interface hepatitis, mild steatosis and a Metavir
ﬁbrosis score of F3. Prior to this biopsy, in 2001, he
had been enrolled in an international clinical trial [9]
where he had received PegasysTM and CopegusTM at
the same doses tested in the INSPIRED-HCV study.
Immediately before enrolment in the latter, the liver
stiﬀness (measured by FibroScan, Echosens, Paris,
France) was 11.1 kPa. At baseline, the patient had a
serum HCV RNA level of 11,000,000 IU/ml (genotype
1b), a HOMA-IR score of 4.64, a marked overweight
(98 kg, 182 cm for a BMI of 29.6 and a waist circumfer-
ence of 120 cm), but no dyslipidemia (serum total cho-
lesterol 5.4 mmol/L, triglycerides 0.3 mmol/l and HDL
cholesterol 2.0 mmol/l) nor arterial hypertension (145/85 mm Hg). After 12 weeks of therapy, the HCV RNA
and the HOMA-IR decreased, respectively, to
64,000 IU/ml and 2.66. The body weight fell to 88 kg
and the waist circumference to 111 cm. No dose changes
of the three drugs had been necessary, as they were all
suﬃciently well tolerated. Despite the fall in viral load,
the patient had his therapy discontinued. In fact, the
2.23 Log reduction in serum HCV RNA was superim-
posable to that observed on occasion of the ﬁrst treat-
ment six years before (2.24 Log), when no
pioglitazone had been added.
Patient #3 was a 59-year-old female, with histologi-
cally documented cirrhosis and a mild steatosis, func-
tionally compensated, related to a HCV genotype 1b
infection. She had no overweight (62 kg, waist circum-
ference 83 cm), no arterial hypertension and a baseline
HOMA-IR score of 5.71. Treatment was very well toler-
ated, with no dose reductions. After 12 weeks of ther-
apy, the HOMA-IR score decreased slightly to 4.52,
while serum HCV RNA went from 410,000 to
61,000 IU/ml. All treatment were stopped. Body weight
and waist circumference were virtually unchanged
(63 kg and 82 cm at week 12).
Patient #4 was a 50-year-old male with histologically
proven cirrhosis, mildly overweight (BMI 25.6, waist cir-
cumference 93 cm) and a poorly controlled arterial
hypertension discovered one year prior to enrolment.
At this time, he was taking lisinopril 20 mg QD and
hydrochlorothiazide 12.5 mg QD but blood pressure
was 170/115 mmHg. Serum cholesterol and triglycerides
were within the normal ranges, but HDL cholesterol was
low (0.5 mmol/L). The baseline HOMA-IR score was
3.79 and serum HCV RNA 1,100,000 IU/ml (genotype
1b). Antiviral treatment was rather well tolerated, with
mild fatigue not necessitating drug dose modiﬁcations.
After 12 weeks, the HOMA-IR was virtually unchanged
(3.57) but HCV RNA had fallen to 11,000 IU/ml. Since
during a previous course of antiviral treatment the vire-
mia had decreased by less than 1 Log, we resorted to
continue the triple therapy. After 24 weeks, however,
viremia had increased slightly to 42,000 IU/ml and all
treatment were deﬁnitely stopped. Body weight
remained unchanged throughout the whole course of
therapy.
Patient #5 was a 46-year-old male. A liver biopsy car-
ried out one year before enrolment had shown mild
activity and portal ﬁbrosis (Metavir A1 F1), with a mild
steatosis aﬀecting 20% of hepatocytes. The patient had
received a 12-week course of combination with Pega-
sysTM and CopegusTM resulting in a 0.95 Log change
in his serum HCV RNA level one year prior to enrol-
ment. His baseline HCV RNA was 2,700,000 IU/ml
(genotype 1a), and the HOMA score 2.88. He had nor-
mal body weight (60 kg, waist circumference 87 cm) and
normal blood pressure. As concomitant medications, he
was receiving olanzapine 15 mg QD and escitalopram
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drugs were well tolerated, but after 12 weeks from start
the HOMA-IR had increased to 3.72, while the serum
HCV RNA had decreased to 300,000 IU/ml, i.e. 0.85
Log, even less than on the occasion of the ﬁrst treat-
ment. Body weight and waist circumference were slightly
reduced (58 kg and 85 cm).
Thus, addition of pioglitazone at start of the antiviral
combination resulted in a weak reduction of the
HOMA-IR score in three patients, while in the remain-
ing two the level of insulin resistance increased (Table 1).
The HCV viral load decreased in all patients, albeit to a
varying extent and unrelated to the HOMA-IR score
variation. Treatment was discontinued at week 12 in
patients 1, 2, 3 and 5 and prolonged in patient 4 until
week 24, to no avail. Based on these discouraging
results, we took the decision to terminate the study.3. Discussion
The rationale of increasing insulin sensitivity in non-
responders lies on the premise that insulin resistant state
directly or indirectly inhibits the antiviral action of IFN-
a, or increases the viral ﬁtness making it more resistant
to therapy, or both. We [10] and others [11–13] have
reported, based on in vitro experimental models and/or
observations in patients, that intracellular factors dys-
regulated by HCV and responsible for the insulin resis-
tant state often play promiscuous roles, as they are also
involved in regulating the IFN-a signaling transduction.
These include some members of the suppressor of cyto-
kine signaling (SOCS) family [10–12] and the protein
phosphatase 2A [13]. Modulating the levels and/or the
activity of these factors may not only reverse hepatic
insulin resistance but also help in establishing the
IFN-a-induced antiviral state at the very site of HCV
replication. However, speciﬁc inhibitors of SOCS family
members and of the protein phosphatase 2A are either
not available for in vivo administration or toxic [14].
Alternatively, one may consider increasing systemic
insulin sensitivity by correcting the circulating levels of
speciﬁc cytokines, such as TNF-a, associated with insu-
lin resistance [15–17], although some caution has been
suggested while administering anti-TNF-a therapy toTable 1
Features of ﬁve chronic hepatitis C patients enrolled into the INSPIRED-
ribavirin + pioglitazone)
# Sex Age
(years)
HCV
genotype
F
score*
BMI Baselin
HOMA
1 F 46 3 2 20.8 2.65
2 M 49 1 3 30.8 4.64
3 F 59 1 4 24.0 5.71
4 M 50 4 4 27.8 3.79
5 M 46 1 1 23.5 2.88
* According to Metavir.chronic hepatitis C patients [18]. Insulin-sensitizers
may also inhibit HCV replication by decreasing serum
free fatty acids overﬂow to hepatocytes, since saturated
and monounsaturated free fatty acids have been shown
to stimulate HCV replication [19].
Thus, although increasing insulin sensitivity may be a
rational option in chronic hepatitis C patients not
responding to current combination therapy, our
approach was clearly inadequate to reach the stated goal.
If this working hypothesis is acceptable, we prompt other
investigators to evaluate diﬀerent schedules.
In our study, it remains to be explained the paradox-
ical increase of the HOMA-IR score observed in two of
our patients during therapy, which was among the rea-
sons that prompted us to stop the trial. It is noteworthy
to mention that both patients were taking additional
drugs for their psychiatric comorbidities: patient #1
was taking duloxetine, a serotonin norepinephrine reup-
take inhibitor, and zopiclone, a cyclopyrrolone-derived
hypnotic agent, while patient #5 was taking escitalop-
ram and olanzapine, an antipsychotic drug. Although
some serotonin reuptake inhibitors may induce
hyperglycemia [20], in general they ameliorate insulin
sensitivity [21]. Furthermore, the dual-mechanism anti-
depressant duloxetine has not been reported to alter glu-
cose homeostasis [21]. Zopiclone overdoses have been
only exceptionally associated with hyperglycemia [22].
On the other hand, olanzapine is well-known for impair-
ing whole body insulin sensitivity [23]. In addition to the
potential eﬀects of these drugs, also the acute adminis-
tration of IFN-a may induce some degree of insulin
resistance in both healthy subjects [24] and chronic hep-
atitis C patients [25]. Thus, although the unwanted
action of IFN-a on glucose metabolism may have been
overcome by pioglitazone in at least three patients, this
beneﬁcial eﬀect may have been nulliﬁed in the two
remaining patients taking drugs for psychiatric indica-
tions. The interactions among all these drugs are how-
ever speculative, but require further studies, in view of
the frequent use of antidepressants in chronic hepatitis
C patients.
Thus, further clinical trials aiming at reducing the insu-
lin resistance in chronic hepatitis C via diﬀerent pharma-
cological interventions are warranted. It is not clear
whether the best approachwould be using thiazolidindionesHCV study, before and after 12 weeks of therapy (PEG-IFN-a2a +
e
-IR
Baseline HCV RNA
(IU/ml)
Week 12
HOMA-IR
Week 12 HCV
RNA (IU/ml)
1,760,000 11.8 1,540,000
11,000,000 2.66 64,000
410,000 4.52 61,000
1,100,000 3.57 11,000
2,700,000 3.72 300,000
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[26], or a biguanide such asmetformin, whose mechanism
of action seems focused on the hepatic AMP-activated
protein kinase [27,28]. Another major question lies in
the modality of the intervention. It is not clear whether
one should start the antiviral retreatment immediately
(as we did) or only once the HOMA-IR score has
decreased to a level predicting a suﬃcient SVR rate [5].
As an alternative, higher dosages of thiazolidindiones
(as compared to what used in the present trial) or metfor-
min may be used, neither can we exclude that insulin
sensitizing therapy should be tailored according to the
infecting HCV genotype [10]. Finally, interactions of
insulin sensitizing agents with other drugs, most notably
those taken for psychiatric comorbidities, should be
considered. Further clinical trials are clearly needed to
address all these important issues.
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